Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus
Open Access
- 1 January 2006
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (47), 7561-7
- https://doi.org/10.3748/wjg.v12.i47.7561
Abstract
The prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) is generally poor if left untreated: a median survival time of 2.7-4.0 mo has been reported. Furthermore, while transcatheter arterial chemoembolization (TACE) has been shown to be safe in selected patients, the median survival time with this treatment is still only 3.8-9.5 mo. Systemic single-agent chemotherapy for HCC with PVTT has failed to improve the prognosis, and the response rates have been less than 20%. While regional chemotherapy with low-dose cisplatin and 5-fluorouracil or interferon and 5-fluorouracil via hepatic arterial infusion has increased the response rate, the median survival time has not exceeded 12 (range 4.5-11.8) mo. Combined treatment consisting of radiation for PVTT and TACE for liver tumor has achieved a high response rate, but the median survival rates have still been only 3.8-10.7 mo. With hepatic resection as monotherapy, the 5-year survival rate and median survival time were reportedly 4%-28.5% and 6-14 mo. The most promising results were reported for combined treatments consisting of hepatectomy and TACE, chemotherapy, or internal radiation. The reported 5-year survival rates and median survival times were 42% and 31 mo for TACE followed by hepatectomy; 36.3% and 22.1 mo for hepatectomy followed by hepatic arterial infusion chemotherapy; and 56% for chemotherapy or internal radiation followed by hepatectomy.Keywords
This publication has 64 references indexed in Scilit:
- Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombusCancer, 2005
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Hepatic arterial infusion of 5‐fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal veinJournal of Surgical Oncology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survivalHepatology, 2000
- Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trialJournal of Hepatology, 1998
- Surgical Intervention for Patients With Stage IV-A Hepatocellular Carcinoma Without Lymph Node MetastasisAnnals of Surgery, 1998
- Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization.American Journal of Roentgenology, 1995
- Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patientsHepatology, 1990
- A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinomaJournal of Hepatology, 1990